Humacyte (NASDAQ:HUMA) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report report published on Monday morning,Benzinga reports. The firm currently has a $25.00 price objective on the stock.

Several other research analysts have also commented on the company. HC Wainwright reduced their price target on Humacyte from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, August 12th. Wall Street Zen cut shares of Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, August 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a report on Saturday, September 27th. Barclays started coverage on shares of Humacyte in a research note on Wednesday, August 27th. They set an “overweight” rating and a $3.50 price objective for the company. Finally, TD Cowen lowered their target price on shares of Humacyte from $5.00 to $3.50 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Humacyte has a consensus rating of “Moderate Buy” and a consensus target price of $9.29.

Humacyte Stock Performance

Shares of Humacyte stock opened at $2.48 on Monday. The company has a current ratio of 2.45, a quick ratio of 1.93 and a debt-to-equity ratio of 2.97. The stock’s fifty day moving average price is $1.78 and its 200-day moving average price is $1.95. The firm has a market cap of $392.76 million, a P/E ratio of -5.51 and a beta of 1.89. Humacyte has a 12 month low of $1.15 and a 12 month high of $6.77.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.09). The firm had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.94 million. On average, equities research analysts expect that Humacyte will post -1.27 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Brady W. Dougan sold 1,100,000 shares of Humacyte stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $1.63, for a total transaction of $1,793,000.00. Following the completion of the sale, the director directly owned 591,685 shares in the company, valued at approximately $964,446.55. The trade was a 65.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Laura E. Niklason sold 1,100,000 shares of the company’s stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $1.63, for a total value of $1,793,000.00. Following the completion of the transaction, the chief executive officer directly owned 591,685 shares in the company, valued at approximately $964,446.55. The trade was a 65.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,482,090 shares of company stock valued at $7,466,382. Corporate insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Humacyte

A number of institutional investors and hedge funds have recently modified their holdings of HUMA. Valeo Financial Advisors LLC acquired a new stake in shares of Humacyte in the second quarter worth $32,000. Squarepoint Ops LLC acquired a new stake in Humacyte during the 2nd quarter worth about $498,000. Thrivent Financial for Lutherans purchased a new position in shares of Humacyte during the 2nd quarter valued at about $496,000. BNP Paribas Financial Markets raised its stake in shares of Humacyte by 257.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 49,039 shares of the company’s stock valued at $102,000 after buying an additional 35,325 shares during the last quarter. Finally, Bridgeway Capital Management LLC acquired a new position in shares of Humacyte in the 2nd quarter valued at about $366,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.